Follow-up | |||||||||||
Normal | Gastritis | AG | IM | LGD | HGD | Invasive neoplasia | Regression | Stable | Progression | ||
n=279 | 40 | 36 | 13 | 183 | 4 | 2 | 2 | 103 (37%) | 165 (59%) | 11 (4%) | |
Baseline | |||||||||||
Normal | – | – | – | – | – | – | – | – | – | – | |
Gastritis | – | – | – | – | – | – | – | – | – | – | |
AG | 11 | 3 | 1 | 2 | 5 | 0 | 0 | 0 | 4 (36%) | 2 (18%) | 5 (45%) |
IM | 244 | 36 | 31 | 10 | 162 | 2 | 2 | 1 | 77 (32%) | 162 (66%) | 5 (2%) |
LGD | 23 | 1 | 4 | 1 | 16 | 1 | 0 | 0 | 22 (96%) | 1 (4%) | 0 (0%) |
HGD* | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 (0%) | 0 (0%) | 1 (100%) |
Gray colour denote the patients who had the same histology at both baseline and during follow-up (mean follow-up 57 months). Above the diagonal indicates patients in whom histology showed progression to a more severe lesion. Under the diagonal indicates patients in whom histology showed regression to a less severe lesion.
*This patient with HGD at baseline was down staged to severe IM at first surveillance endoscopy. At second surveillance endoscopy, an early gastric cancer was found.
AG, atrophic gastritis; HGD, high-grade adenoma/dysplasia.; IM, intestinal metaplasia; LGD, low-grade adenoma/dysplasia.